Regeneron Pharmaceuticals ((REGN)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: The clinical study titled A Multicenter Open-label Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis aims to evaluate the pharmacokinetics and safety of Dupilumab in young participants suffering from Prurigo Nodularis. This study is significant as it targets a pediatric population, potentially expanding treatment options for this chronic skin condition.
Intervention/Treatment: The study tests Dupilumab, an experimental drug administered subcutaneously. It is designed to treat Prurigo Nodularis by modulating the immune response, offering a potential therapeutic option for children and adolescents.
Study Design: This Phase 3 study is interventional with a single-group assignment. It is open-label, meaning no masking is involved, and its primary purpose is treatment. Participants undergo a 42 to 44-week process, including screening, treatment, and follow-up periods.
Study Timeline: The study began on February 27, 2024, with primary completion expected in 2025. The last update was submitted on August 19, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
Market Implications: This study update could positively impact the stock performance of Regeneron Pharmaceuticals and Sanofi by potentially expanding Dupilumab’s market to include pediatric patients. This development may enhance investor sentiment, especially if the study results are favorable, positioning these companies ahead of competitors in the dermatology sector.
The study is ongoing, with further details available on the ClinicalTrials portal.